Literatur
-
1
Felsenberg D et al.
Prevalence of vertebral spinal deformities in women and men in Germany. EVOS group in Germany.
Med Klin.
1998;
93
31-34
-
2
WHO .
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.
World Health Organ Tech Rep Ser.
1994;
843
-
3
Cooper C et al.
Population-based study of survival after osteoporotic fractures.
Am J Epidemiol.
1993;
137
1001-1005
-
4
Pfeilschifter J.
2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines.
Exp Clin Endocrinol Diabetes.
2006;
114
611-622
-
5
Podsiadlo D, Richardson S.
The timed “Up & Go”: a test of basic functional mobility for frail elderly persons.
J Am Geriatr Soc.
1991;
39
142-148
-
6
Guralnik J M et al.
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability.
N Engl J Med.
1995;
332
556-561
-
7
Gluer C C et al.
Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study.
J Bone Miner Res.
2004;
19
782-793
-
8
Schott A M et al.
Should age influence the choice of quantitative bone assessment technique in elderly women? The EPIDOS study.
Osteoporos Int.
2004;
15
196-203
-
9
Tsai K S et al.
Impaired vitamin D metabolism with aging in women. Possible role in pathogenesis of senile osteoporosis.
J Clin Invest.
1984;
73
1668-1672
-
10
Bischoff-Ferrari H A et al.
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes.
Am J Clin Nutr.
2006;
84
18-28
-
11
Siggelkow H.
Vitamin D and old age.
MMW Fortschr Med.
2007;
149
36-37
-
12
Eastell R.
Aromatase inhibitors and bone.
J Steroid Biochem Mol Biol.
2007;
106
157-161
-
13
Mincey B A et al.
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Clin Breast Cancer.
2006;
7
127-132
-
14
Hillner B E et al.
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.
J Clin Oncol.
2003;
21
4042-4057
-
15
Aapro M et al.
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.
Ann Oncol.
2007;
-
16
Winer E P et al.
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
J Clin Oncol.
2005;
23
619-629
-
17
Wisser J et al.
Changes in bone density and metabolism in pregnancy.
Acta Obstet Gynecol Scand.
2005;
84
349-354
-
18
Lanham S A et al.
Intrauterine programming of bone. Part 1: Alteration of the osteogenic environment.
Osteoporos Int.
2007;
-
19
Lanham S A et al.
Intrauterine programming of bone. Part 2: Alteration of skeletal structure.
Osteoporos Int.
2007;
-
20
Kovacs C S.
Calcium and bone metabolism during pregnancy and lactation.
J Mammary Gland Biol Neoplasia.
2005;
10
105-118
-
21
Hellmeyer L et al.
The use of i. v. bisphosphonate in pregnancy-associated osteoporosis: case study.
Exp Clin Endocrinol Diabetes.
2007;
115
139-142
-
22
Steib-Furno S et al.
Pregnancy-related hip diseases: incidence and diagnoses.
Joint Bone Spine.
2007;
74
373-378
-
23
O'Sullivan S M et al.
Bisphosphonates in pregnancy and lactation-associated osteoporosis.
Osteoporos Int.
2006;
17
1008-1012
Priv. Doz. Dr. med. H. Siggelkow
Fachärztin für Innere Medizin · Endokrinologie und Diabetologie (DDG) · Osteologin DVO · Endokrinologikum Göttingen
Von-Siebold-Str. 3
37075 Göttingen
Email: heide.siggelkow@endokrinologikum.com
Universität Göttingen · Bereich Humanmedizin · Abt. für Gastroenterologie und Endokrinologie
Robert-Koch-Str. 40
37075 Göttingen
Email: hsiggel@med.uni-goettingen.de
